DAXI Program - DAXI Aesthetics: Represents a $2 billion global opportunity, with positive Phase 3 studies in Glabellar Lines and an expected BLA filing in Fall 2019, targeting a U S approval/launch in 2020[7, 82] - DAXI Therapeutics: Addresses a $2.5 billion global opportunity, with Phase 3 underway in Cervical Dystonia and Phase 2 studies in Upper Limb Spasticity and Plantar Fasciitis, with clinical results expected in 2H 2020[7, 82] - DAXI demonstrates high efficacy and a 24-week duration in Glabellar Lines[7, 82] - SAKURA 1 & 2 pivotal trials showed 73.6% and 74.0% of subjects achieving ≥ 2-point composite response vs placebo at 0% and 1% respectively at week 4[26] - DAXI's SAKURA program supports a 6-month duration on label for glabellar lines[39] Biosimilar Program - Biosimilar to BOTOX® targets a $3.6 billion global market, with a confirmed viable 351(k) pathway[8, 63, 83] - Revance has a global partnership with Mylan for the biosimilar program, receiving $30 million in upfront payments and potential milestones & royalties[8, 63, 83] Market Overview - The global neuromodulator market is a $4.5 billion opportunity, expected to reach $7.7 billion by 2025[12] - Aesthetics accounts for 44% of the neuromodulator market, while therapeutics represents 56%[13] Financial Status - The company has $242 million in cash, cash equivalents, and short-term investments as of June 30, 2019, with no debt[78] - FY 2019 GAAP operating expenses are projected to be $173–185 million, and non-GAAP operating expenses are projected to be $148–158 million[79]

Revance Therapeutics, Inc. (NASDAQ:RVNC) Q2 2019 Results Earnings Conference Call August 5, 2019 4:30 PM ET Company Participants Jeanie Herbert - Senior Director of IR & Corporate Communications Daniel Browne - Co-Founder, President, CEO Tobin Schilke - CFO & Principal Accounting Officer Conference Call Participants Annabel Samimy - Stifel Ken Cacciatore - Cowen & Company Seamus Fernandez - Guggenheim David Amsellem - Piper Jaffray David Maris - Wells Fargo Tim Lugo - William Blair Douglas Tsao - H.C. Wainw ...